Phoenix Life Announces $40 Million Capital Raise in Conjunction with TABOR Family Office Conference

DENVER, CO, May 01, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE - Phoenix Life Sciences International Limited (OTC: PLSI) (“Phoenix Life” or the “Company”), an adaptive healthcare solutions company, today announced that it will be executing a $40 million capital raise and presenting at the TABOR Family Office Conference in Sea Island, Georgia.

The offering terms of Phoenix Life’s capital raise include a $40 million raise with a minimum subscription of 2,000 shares, or $25,000. In total, the Company is offering 3.2 million shares of the Company’s common stock at a purchase price of $12.50 per share to accredited investors, including qualified family offices and institutional investors. Phoenix Life intends to dedicate the proceeds of this capital raise to furthering the company’s international expansion, including the Global Production Facility and National Network of Community Clinics and Dispensing Pharmacies.

“We are excited to share this important news after just recently completing our annual report filings,” said Phoenix Life CEO and Founder, Martin Tindall. “With this capital raise, we will be able to bring online 100 acres of cultivation capacity and pharmaceutical production of Phoenix Metabolic and other Phoenix Life products to supply much needed products for up to 1,000,000 patients. The first of a multi-phase approach to transforming the future of global healthcare.”

The TABOR Family Office Conference is invitation-only and will consist of approximately 50 high net worth Family Offices and 25 to 30 Investment Managers. Phoenix Life is one of the few companies chosen to present at the conference.

TABOR Capital Conferences is an alternative investment conference organizer. The Firm’s key objective is to bring Elite Investment Managers together with Investors in small forums that allow for meaningful discussions and the opportunity to foster new relationships. TABOR’S goal is to host small, specialized conferences that are beneficial for all attendees and ultimately provide value after the completion of each event.

For more information on Phoenix Life’s capital raise and accompanying Private Placement Memorandum, please visit the company’s Investor Portal at

To learn more about Phoenix Life Sciences International, please visit

About Phoenix Life Sciences International Limited

Phoenix Life Sciences International Limited is an adaptive healthcare solutions company. Our business is to advance research and integrate programs and manufacturing of products that target and treat diabetes, pain, cancer, and address psychological, gastrointestinal, autoimmune, neurological and sleep disorders. We strive to create partnerships and integrate these programs for human health into communities worldwide as part of our Global Health Initiative.


Information contained in this press release regarding Phoenix Life Sciences International, Limited and its subsidiaries, (the “Companies”) may constitute forward-looking statements or statements which may be deemed or construed to be forward-looking statements. The words “plan”, “forecast”, “anticipates”, “estimate”, “project”, “intend”, “expect”, “should”, “believe,” and similar expressions are intended to identify forward-looking statements. These forward-looking statements involve, and are subject to, known and unknown risks, uncertainties and other factors which could cause the Company’s actual results, performance (financial or operating) or achievements to differ from the future results, performance (financial or operating) or achievements expressed or implied by such forward-looking statements. The risks, uncertainties and other factors are more fully discussed in the Company’s filings with the U.S. Securities and Exchange Commission. All forward-looking statements attributable to the Companies herein are expressly qualified in their entirety by the above-mentioned cautionary statement. The Companies disclaim any obligation to update forward-looking statements contained in this press release, except as may be required by law.


These statements have not been evaluated by the FDA and therefore the products sold by Phoenix Life Sciences International are not available in the U.S.


Phoenix Life Sciences International does not sell or distribute any products in the United States that are in violation of the United States Controlled Substances Act (US.CSA). This company does not grow, sell, and distribute cannabis-based products in the United States and is solely involved with the legal distribution of medical cannabis-based products within certain international markets outside of the United States.


Contact Data